Page last updated: 2024-11-04

sulfasalazine and Bone Loss, Perimenopausal

sulfasalazine has been researched along with Bone Loss, Perimenopausal in 1 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Research Excerpts

ExcerptRelevanceReference
"To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA)."9.10Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. ( Beresford, JN; Bhalla, AK; Compston, JE; Kounali, D; Minaur, NJ; Vedi, S, 2002)
"To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA)."5.10Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. ( Beresford, JN; Bhalla, AK; Compston, JE; Kounali, D; Minaur, NJ; Vedi, S, 2002)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Minaur, NJ1
Kounali, D1
Vedi, S1
Compston, JE1
Beresford, JN1
Bhalla, AK1

Trials

1 trial available for sulfasalazine and Bone Loss, Perimenopausal

ArticleYear
Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density.
    Rheumatology (Oxford, England), 2002, Volume: 41, Issue:7

    Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Dose-Respons

2002